Anti-tumorigenic efficacy of tangeretin in liver cancer - an in-silico approach. - GreenMedInfo Summary

BACKGROUND: Liver cancer is otherwise known as Hepatic cancer which originated from the liver. Hepatocellular carcinoma (HCC) is the common primary Liver cancer and is one of the emerging problems worldwide. Very few treatments are available to treat HCC, because the molecular mechanism and other HCC mechanisms are still unclear. Cyclooxygenase 2 (COX-2), one of the most promising targets for Hepatocellular Carcinoma and it is one of the dimeric enzymes which convert Arachidonic acid into Prostaglandin H2 in the step of Prostaglandin biosynthesis. Several, natural bioactive compounds involved in the treatment of various types of cancer. Tangeretin, one of the natural polymethoxyflavone which is present in the peel of citrus fruits and it also acts as an Anti-oxidant modulator and Anti-cancerous.

METHODS: Computational approaches like Molecular docking and Molecular dynamics was performed to identify the potential inhibitor for Hepatocellular Carcinoma.

OBJECTIVES: The main objective of this study is to find a suitable inhibitor for Hepatocellular Carcinoma.

RESULTS: In this study, COX-2 considered as the potential target for Hepatocellular Carcinoma which was examined with Tangeretin.

CONCLUSION: Tangeretin was screened against C0X-2 which includes Molecular Docking, DFT analysis, ADMET prediction, and Molecular Dynamics simulation. Tangeretin had good docking scores, fulfill the pharmacological properties through ADMET prediction, and the Protein-Ligand complex had good stability in Molecular Dynamics simulation.